Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 20/20 | 1.00 |
| ▸ | GBA2 | Q9HCG7 | 20/20 | 1.00 |
| ▸ | GBA1 | P04062 | 19/20 | 1.00 |
| ▸ | LCT | P09848 | 12/20 | 1.00 |
| ▸ | SI | P14410 | 9/20 | 1.00 |
| ▸ | MGAM | O43451 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nizubaglustat SCHEMBL17132915 | 1.00 | UGCG (1.00) | UGCGGBA2GBA1LCTSI | |
| Nizubaglustat SCHEMBL17132924 | 1.00 | UGCG (1.00) | UGCGGBA2GBA1LCTSI | |
| Nizubaglustat SCHEMBL17132925 | 1.00 | UGCG (1.00) | UGCGGBA2GBA1LCTSI | |
| SCHEMBL25962102 | 0.89 | UGCG (0.80) | UGCGGBA2GBA1LCTSI | |
| SCHEMBL19224235 | 0.89 | UGCG (0.79) | UGCGGBA2GBA1LCTSI | |
| SCHEMBL20862311 | 0.89 | UGCG (0.79) | UGCGGBA2GBA1LCTSI | |
| SCHEMBL19224234 | 0.89 | UGCG (0.79) | UGCGGBA2GBA1LCTSI | |
| SCHEMBL17132965 | 0.88 | UGCG (1.00) | UGCGGBA2GBA1LCTSI | |
| SCHEMBL19224258 | 0.88 | UGCG (1.00) | UGCGGBA2GBA1LCTSI | |
| SCHEMBL20682892 | 0.88 | UGCG (1.00) | UGCGGBA2GBA1LCTSI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3461812-B1 | N-(5-(BIPHEN-4-YLMETHYLOXY)PENTYL)-SUBSTITUTED IMINOSUGARS AS INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE | ACAD MEDISCH CT (NL) | 2021-10-13 | — | — | EP | disclosed |
| US-10590082-B2 | N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase | ACADEMISCH MEDISCH CENTRUM (NL) | 2020-03-17 | — | — | US | disclosed |
| US-20190144388-A1 | N-(5-((ARYL OR HETEROARYL)METHYLOXY)PENTYL)-SUBSTITUTED IMINOSUGARS AS INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE | Stichting Amsterdam UMC (NL) | 2019-05-16 | — | — | US | disclosed |
| EP-3461812-A1 | N-(5-(BIPHEN-4-YLMETHYLOXY)PENTYL)-SUBSTITUTED IMINOSUGARS AS INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE | Academisch Medisch Centrum (NL) | 2019-04-03 | — | — | EP | disclosed |
| US-10189784-B2 | N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase | ACADEMISCH MEDISCH CENTRUM (NL) | 2019-01-29 | — | — | US | disclosed |
| US-20170226058-A1 | N-(5-((ARYL OR HETEROARYL)METHYLOXY)PENTYL)-SUBSTITUTED IMINOSUGARS AS INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE | Stichting Amsterdam UMC (NL) | 2017-08-10 | — | — | US | disclosed |
| US-20170226058-A1 | N-(5-((ARYL OR HETEROARYL)METHYLOXY)PENTYL)-SUBSTITUTED IMINOSUGARS AS INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE | Stichting Amsterdam UMC (NL) | 2017-08-10 | — | — | US | disclosed |
| WO-2015147639-A1 | N-(5-((ARYL OR HETEROARYL)METHYLOXY)PENTYL)-SUBSTITUTED IMINOSUGARS AS INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE | ACADEMISCH MEDISCH CENTRUM (NL) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144388-A1 | N-(5-((ARYL OR HETEROARYL)METHYLOXY)PENTYL)-SUBSTITUTED IMINOSUGARS AS INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE | GBA2, GBA1, GALC | UGCG 9/4885GBA2 1/4885GBA1 2/4885 |
| US-20170226058-A1 | N-(5-((ARYL OR HETEROARYL)METHYLOXY)PENTYL)-SUBSTITUTED IMINOSUGARS AS INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE | GBA2, GBA1, GALC | UGCG 9/4885GBA2 1/4885GBA1 2/4885 |
| US-10189784-B2 | N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase | GBA2, GBA1, GALC | UGCG 9/4885GBA2 1/4885GBA1 2/4885 |
| US-10590082-B2 | N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase | GBA2, GBA1, GALC | UGCG 9/4885GBA2 1/4885GBA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.